MD890Z - Метод прогнозирования риска развития дисгормональной гиперплазии молочной железы - Google Patents
Метод прогнозирования риска развития дисгормональной гиперплазии молочной железы Download PDFInfo
- Publication number
- MD890Z MD890Z MDS20140077A MDS20140077A MD890Z MD 890 Z MD890 Z MD 890Z MD S20140077 A MDS20140077 A MD S20140077A MD S20140077 A MDS20140077 A MD S20140077A MD 890 Z MD890 Z MD 890Z
- Authority
- MD
- Moldova
- Prior art keywords
- risk
- hyperplasia
- mammary gland
- developing
- dyshormonal
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 17
- 210000005075 mammary gland Anatomy 0.000 title claims description 25
- 206010020718 hyperplasia Diseases 0.000 title claims description 21
- 239000012634 fragment Substances 0.000 claims abstract description 9
- 210000004369 blood Anatomy 0.000 claims abstract description 5
- 239000008280 blood Substances 0.000 claims abstract description 5
- 210000002381 plasma Anatomy 0.000 claims description 4
- 238000003127 radioimmunoassay Methods 0.000 claims description 3
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 claims description 2
- 108010066302 Keratin-19 Proteins 0.000 claims description 2
- 108010036226 antigen CYFRA21.1 Proteins 0.000 abstract description 8
- 108010076876 Keratins Proteins 0.000 abstract description 7
- 102000011782 Keratins Human genes 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 2
- 206010006256 Breast hyperplasia Diseases 0.000 abstract 2
- 230000007170 pathology Effects 0.000 description 10
- 239000003550 marker Substances 0.000 description 9
- HVDGDHBAMCBBLR-UHFFFAOYSA-N Enterolactone Natural products OC1=CC=CC(CC2C(C(=O)OC2)CC=2C=C(O)C=CC=2)=C1 HVDGDHBAMCBBLR-UHFFFAOYSA-N 0.000 description 8
- HVDGDHBAMCBBLR-WMLDXEAASA-N enterolactone Chemical compound OC1=CC=CC(C[C@@H]2[C@H](C(=O)OC2)CC=2C=C(O)C=CC=2)=C1 HVDGDHBAMCBBLR-WMLDXEAASA-N 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 7
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- 101150009046 Tnfrsf1a gene Proteins 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 206010058314 Dysplasia Diseases 0.000 description 2
- 108010008707 Mucin-1 Proteins 0.000 description 2
- 102000007298 Mucin-1 Human genes 0.000 description 2
- 206010000210 abortion Diseases 0.000 description 2
- 231100000176 abortion Toxicity 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 206010063057 Cystitis noninfective Diseases 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000003947 acalculous cholecystitis Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 201000003139 chronic cystitis Diseases 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 201000003159 intraductal papilloma Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 230000009247 menarche Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 201000002243 skin lipoma Diseases 0.000 description 1
- 206010043688 thyroid adenoma Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Изобретение относится к медицине, в частности к маммологии, и может быть использовано для прогнозирования риска развития дисгормональной гиперплазии молочной железы.Согласно изобретению, заявленный метод состоит в том, что забирают 1,0 мл крови, отделяют плазму и посредством радиоимунного метода определяют количество фрагментов цитокератина 19 (Cyfra 21-1), в случае, когда количество варьирует в интервале 1,7…2,4 нг/мл, прогнозируют повышенный риск, в интервале 1,2…1,6 нг/мл - средний риск и в интервале 0,7…1,1 нг/мл - минимальный риск развития дисгормональной гиперплазии молочной железы.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20140077A MD890Z (ru) | 2014-05-30 | 2014-05-30 | Метод прогнозирования риска развития дисгормональной гиперплазии молочной железы |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20140077A MD890Z (ru) | 2014-05-30 | 2014-05-30 | Метод прогнозирования риска развития дисгормональной гиперплазии молочной железы |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MD890Y MD890Y (ru) | 2015-03-31 |
| MD890Z true MD890Z (ru) | 2015-10-31 |
Family
ID=52780270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDS20140077A MD890Z (ru) | 2014-05-30 | 2014-05-30 | Метод прогнозирования риска развития дисгормональной гиперплазии молочной железы |
Country Status (1)
| Country | Link |
|---|---|
| MD (1) | MD890Z (ru) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD1119Z (ru) * | 2016-05-06 | 2017-09-30 | Оксана ОДОБЕСКУ | Метод прогнозирования риска малигнизации филлоидной опухоли молочной железы |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2263319C2 (ru) * | 2003-07-31 | 2005-10-27 | Ростовский научно-исследовательский онкологический институт МЗ РФ | Способ прогнозирования рецидива рака молочной железы |
| MD2872F1 (en) * | 2005-03-04 | 2005-10-31 | Mihail SURGUCI | Method of prognosticating the risk of appearance of the mammary dyshormonal hyperplasia |
| RU2480763C1 (ru) * | 2012-03-07 | 2013-04-27 | Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" | Способ прогнозирования риска развития доброкачественной дисплазии молочной железы у женщин с генитальным эндометриозом |
-
2014
- 2014-05-30 MD MDS20140077A patent/MD890Z/ru not_active IP Right Cessation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2263319C2 (ru) * | 2003-07-31 | 2005-10-27 | Ростовский научно-исследовательский онкологический институт МЗ РФ | Способ прогнозирования рецидива рака молочной железы |
| MD2872F1 (en) * | 2005-03-04 | 2005-10-31 | Mihail SURGUCI | Method of prognosticating the risk of appearance of the mammary dyshormonal hyperplasia |
| RU2480763C1 (ru) * | 2012-03-07 | 2013-04-27 | Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" | Способ прогнозирования риска развития доброкачественной дисплазии молочной железы у женщин с генитальным эндометриозом |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD1119Z (ru) * | 2016-05-06 | 2017-09-30 | Оксана ОДОБЕСКУ | Метод прогнозирования риска малигнизации филлоидной опухоли молочной железы |
Also Published As
| Publication number | Publication date |
|---|---|
| MD890Y (ru) | 2015-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Huang et al. | Thyroid-stimulating hormone, thyroid hormones, and risk of papillary thyroid cancer: a nested case–control study | |
| Tchou et al. | Fibroblast activation protein expression by stromal cells and tumor-associated macrophages in human breast cancer | |
| Hecking et al. | Tumoral PD-L1 expression defines a subgroup of poor-prognosis vulvar carcinomas with non-viral etiology | |
| López-Verdín et al. | E-Cadherin gene expression in oral cancer: clinical and prospective data | |
| Bochen et al. | Effect of 3q oncogenes SEC62 and SOX2 on lymphatic metastasis and clinical outcome of head and neck squamous cell carcinomas | |
| Cheung et al. | Granulin–epithelin precursor renders hepatocellular carcinoma cells resistant to natural killer cytotoxicity | |
| Weyerer et al. | Immunohistochemical and molecular characterizations in urothelial carcinoma of bladder in patients less than 45 years | |
| Ramos-Vega et al. | Immunohistochemical analysis of cancer-associated fibroblasts and podoplanin in head and neck cancer | |
| CN110007082A (zh) | Icosl蛋白在制备乳腺癌预后评估试剂盒中的应用 | |
| Pryczynicz et al. | Immunohistochemical expression of MMP-7 protein and its serum level in colorectal cancer | |
| Wu et al. | PIWIL1 interacting RNA piR-017724 inhibits proliferation, invasion, and migration, and inhibits the development of HCC by silencing PLIN3 | |
| Roy et al. | KLF4 expression in the surgical cut margin is associated with disease relapse of oral squamous cell carcinoma | |
| Albu et al. | Diagnosis problems in a case of ovarian tumor-case presentation | |
| Nazarizadeh et al. | Evaluation of local and circulating osteopontin in malignant and benign primary bone tumors | |
| MD890Z (ru) | Метод прогнозирования риска развития дисгормональной гиперплазии молочной железы | |
| EP3063296A1 (en) | Epithelial-mesenchymal transition in circulating tumor cells (ctcs) negatives for cytokeratin (ck) expression in patients with non-metastatic breast cancer | |
| Bandala et al. | Association of histopathological markers with clinico-pathological factors in Mexican women with breast cancer | |
| Huang et al. | CD 103 expression in normal epithelium is associated with poor prognosis of colorectal cancer patients within defined subgroups | |
| Takano et al. | Initial panel of immunocytochemical markers for identification of primary carcinoma site for effusions and peritoneal washings from women | |
| CN110441523A (zh) | Atad2蛋白作为标志物在判断卵巢癌增殖状态中的应用 | |
| Devrim et al. | Coexistence of CD44 and Ki-67 as the prognostic markers in renal cell carcinoma | |
| Wang et al. | The clinicopathological features of metastatic tumors of the bladder: analysis of 25 cases | |
| JP2022539754A (ja) | 子宮内膜受容期を予測する方法 | |
| Tanaka et al. | Apoptotic function of tumor-associated antigen RCAS1 in oral squamous cell carcinoma | |
| Gouadfel et al. | The potential role of Epstein-Barr Virus in breast cancer development |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG9Y | Short term patent issued | ||
| KA4Y | Short-term patent lapsed due to non-payment of fees (with right of restoration) | ||
| MM4Y | Short-term patent definitely lapsed due to non-payment of fees |